Skip to main content
ScholarsBetaWeill Cornell Medicine

Overview

The Elemento lab combines Big Data analytics with experimentation to develop entirely new ways to help prevent, diagnose, understand, treat and ultimately cure cancer. Our research involves routine use of ultrafast DNA sequencing, proteomics, high-performance computing, mathematical modeling, and artificial intelligence/machine learning.

Highlights

  1. 1
    Nature methods · 2022
    JMJuan Miguel MosqueraOEOlivier Elemento
    PMID: 36316562PMCID: PMC11102857DOISenior author74 citations
  2. 2
    Cell reports · 2021
    JWJessica WhiteJGJuan Garcia-MedinaOEOlivier Elemento
    PMID: 34879281DOISenior author64 citations
  3. 3
    iScience · 2021
    OEOlivier Elemento
    PMID: 33997679PMCID: PMC8099498DOISenior author31 citations

Publications

579 publications

Funding

128 grantsView NIH portfolio on RePORTER ↗

Active

45 grants
  • PI
    AI-Human Discovery Engines for Mechanistic Cancer Biology
    National Cancer Institute · 2026–2031
    DP1CA324880-01
  • Co-I
    Caloric restriction to enhance cancer immunoprevention
    National Cancer Institute · 2026–2031
    R01CA311885-01
  • Co-I
    Spatial omics to understanding HBV control in people with HIV coinfection
    National Institute of Allergy and Infectious Diseases · 2025–2030
    R01AI195435-01
  • Co-I
    Germline-somatic interactions as drivers and therapeutic targets in bladder cancer
    American Cancer Society · 2026–2030
    RSG-25-1511719-01-ET
  • Co-I
    Immune analysis of the HBsAg seroclearance response terminating chronic HBV
    National Institute of Allergy and Infectious Diseases · 2024–2029 · via The Regents of the University of California, San Francisco
    R01AI187598-01
  • PI
    SAMBAI: Societal, Ancestry and Molecular Biology Analyses of Inequalities
    Cancer Research UK · 2024–2029
    CGCATF-2023/100030
  • Co-I
    Targeting APOBEC3A-induced genetic heterogeneity and drug resistance in bladder cancer
    National Cancer Institute · 2023–2028
    R37CA279737-01A1
  • Sub-PI
    Deep learning based 3D network biology knowledge portal for precision oncology
    National Cancer Institute · 2025–2028 · via Cornell University - Ithaca
    U01CA294154-02
  • Co-I
    Targeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancer
    National Cancer Institute · 2023–2028
    R01CA271915-01A1
  • Co-I
    Targeting Ovarian Cancer Metastasis: From Pre-metastatic Niches to Liquid Biopsies
    Pershing Square Foundation · 2025–2028
    PSF 251938-01
  • Sub-PI
    Bone marrow-derived myeloid cell dysregulation in malignant progression of glioma
    National Institute of Neurological Disorders and Stroke · 2023–2028 · via The Research Institute at Nationwide Children's Hospital
    R01NS127984-02
  • Co-I
    Elucidating single cell changes in neurogenic brain regions during HIV and cannabinoid exposure
    National Institute on Drug Abuse · 2023–2028
    U01DA058527-01
  • Co-I
    Immunoregulatory role of lung-resident club cell factors in lung cancer
    National Cancer Institute · 2023–2028
    R01CA271545-01A1
  • Sub-PI
    HLA-E and NKG2A define a novel immune checkpoint axis in non-muscle-invasive bladder cancer
    National Cancer Institute · 2023–2028 · via Icahn School of Medicine at Mount Sinai
    R01CA269954-04
  • Co-I
    ER stress-driven IRE1a-XBP1 signaling in lung cancer
    National Cancer Institute · 2023–2028
    R01CA271619-01A1
  • KP
    Targeting Unmet Needs For B-cell Lymphomas
    Leukemia & Lymphoma Society · 2022–2027
    LLS 7027-23 Project 1
  • Co-I
    Center for Lupus Research
    National Inst of Arthritis & Musculoskeletal & Skin Diseases · 2017–2027· 2 renewals
    P50AR070594-06
  • Co-I
    CAP-IT Center for LNP RNA Immunoprevention
    National Cancer Institute · 2022–2027
    U54CA272688-01
  • Co-I
    HOPE - HIV Obstruction by Programmed Epigenetics
    National Institute of Allergy and Infectious Diseases · 2021–2027 · via University of California, San Francisco
    UM1AI164559-04
  • KP
    Clinical and Translational Science Center - UL1
    National Center for Advancing Translational Sciences · 2017–2027· 3 renewals
    UL1TR002384-06
  • Co-I
    Targeting HIV reservoirs in the CNS with CAR/CXCR5 T cells for the long-term remission of HIV.
    National Institute of Mental Health · 2022–2027 · via University of Minnesota
    R01MH130177-01
  • Co-I
    Preventing follicular lymphoma progression and transformation through precision therapy
    National Cancer Institute · 2022–2027
    R01CA270245-01
  • Co-I
    The Impact of Spaceflight and Radiation on Clonal Hematopoiesis
    National Aeronautics and Space Administration · 2023–2027
    80NSSC23K0832
  • Sub-PI
    Personalized in vitro models to advance precision health equity
    National Cancer Institute · 2024–2027 · via Leidos Biomedical Research
    HHSN261201500003I
  • MPI
    Early life respiratory viral infections shape immune development trajectories - Data Management Analysis Core
    National Institute of Allergy and Infectious Diseases · 2023–2027 · via St. Jude Children's Research Hospital
    U19AI168632-02
  • Co-I
    Pre-malignant mutation landscape and risk factors for progression to hematologic cancers
    National Cancer Institute · 2021–2027
    R01CA248747-01A1
  • Co-I
    Adaptable tissue-specific endothelial cells for organ regeneration
    National Heart, Lung, and Blood Institute · 2020–2027
    R35HL150809-01
  • KP
    Biomarkers of response in primary mediastinal B-cell lymphoma: Defining tumor microenvironment signatures
    Hyundai Hope on Wheels Foundation · 2024–2026
    HHWF 240412-01
  • Sub-PI
    Voice as a Biomarker of Health: Building an Ethically Sourced, Bioaccoustic Database to Understand Disease Like Never Before
    Office of the Director, NIH · 2022–2026 · via University of South Florida· 2 renewals
    OT2OD032720-01
  • Co-I
    Converting HR+ Breast Cancer Into an Individualized Vaccine
    U.S. Department of Defense · 2019–2026
    W81XWH-19-1-0141
  • Co-I
    Converting HR+ Breast Cancer Into an Individualized Vaccine
    U.S. Department of Defense · 2019–2026
    W81XWH-19-1-0142
  • Co-I
    Therapeutic targeting of breast cancer and host immune responses at inflection points in the disease trajectory
    U.S. Department of Defense · 2021–2026
    W81XWH-21-2-0034
  • MPI
    The joint WCM-NYGC Center for Functional and Clinical Interpretation of Tumor Profiles
    National Cancer Institute · 2021–2026
    U24CA264032-05
  • Co-I
    Novel Complex Structural Variants And Epigenetic Alterations Link The Genomes Of Prostate Cancer In African Americans With Outcome Disparity.
    U.S. Department of Defense · 2021–2026
    W81XWH-21-1-0762
  • PI
    Exploring the potential of valproic acid (VPA) as a pleiotropic regulator of the tumor-immune microenvironment in colorectal cancer
    Istituto Nazionale Tumori IRCCS Fondazione G. Pascale (National Cancer Institute IRCCS · 2025–2026Contract
    SA 250233-01
  • PI
    SAMBAI: Societal, Ancestry and Molecular Biology Analyses of Inequalities
    National Cancer Institute · 2024–2026
    OT2CA297580-01
  • Co-I
    Molecular Fingerprinting of Lupus in Children
    Lupus Research Alliance · 2022–2026
    LRA 213987-01
  • Co-I
    Targeting Latency Switch in EBV+ Lymphomas
    National Cancer Institute · 2022–2026
    R37CA262517-01A1
  • Co-I
    Negative feedback regulation of growth factor signaling in adult spermatogonial stem cells
    Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2021–2026
    R01HD101452-03
  • KP
    Harnessing Single Cell Epigenome-wide profiling of Myeloid cells to Compare and Contrast Alzheimer's from HIV-Associated Cognitive Dysfunction
    National Institute on Aging · 2020–2026
    R01AG063846-01A1
  • Co-I
    LLS SCOR Project: Studying Epigenetic Targeting of Hematological Malignancies
    Leukemia & Lymphoma Society · 2024–2026 · via University of Florida
    7037-25
  • KP
    Targeting cytidine deaminase-induced chromosomal instability as a driver of metastasis in bladder cancer
    Starr Cancer Consortium · 2023–2025
    I16-0054
  • Co-I
    Sphingolipid Biology of macrophage in Coronary Atherosclerosis Development and Progression
    National Heart, Lung, and Blood Institute · 2021–2025
    No publications yet
    R01HL158771-01
  • Co-I
    Janssen Biopharma Agreement
    Janssen Biotech Inc. · 2020–2025BioPharma Alliance
    BP 212999-01
  • Co-I
    Role of the stromal microenvironment in B-cell lymphoma progression and immune escape
    National Cancer Institute · 2019–2025
    R01CA242069-01A1
Completed grants (83)
  • PI
    Research collaboration agreement w/ Eli Lilly and Company
    Eli Lilly and Company · 2019–2025BioPharma Alliance
    ELC 202676-03
  • KP
    Targeting APOBEC3A-induced chromosomal instability as a driver of metastasis in bladder cancer
    U.S. Department of Defense · 2023–2025
    HT9425-23-1-0790
  • Co-I
    Mechanism-Based Targeting of Mantle Cell Lymphoma
    National Cancer Institute · 2018–2025
    P01CA214274-05
  • Co-I
    Targeting Epigenetic Circuits in B-Cell Lymphomas
    National Cancer Institute · 2018–2025
    R35CA220499-01A1
  • PI
    Biopharma Agreement with Sanofi US
    Sanofi S.A. · 2023–2025BioPharma Alliance
    BP 241938-01
  • Co-I
    Colorectal Cancer (CRC) Cellular Heterogeneity, Metastasis, and a Spatially-resolved Molecular Atlas for Colon
    Gastro-Intestinal Research Foundation · 2022–2025
    GIRF 227268-01
  • KP
    Lung Cancer Initiative at Johnson & Johnson-Weill Cornell Collaboration
    Johnson & Johnson · 2020–2025BioPharma Alliance
    JJEI 213094-01
  • PI
    Volastra Inc. Biopharma
    Volastra · 2020–2025BioPharma Alliance
    VI 211768-01
  • Co-I
    The impact of changes in chromatin architecture on cancer phenotypes and tumor progression
    National Cancer Institute · 2019–2025 · via New York University Medical Center
    P01CA229086-05
  • Co-I
    H3.3-mediated epigenetic regulation of developmental bivalent genes for reprogramming and differentiation
    National Institute of General Medical Sciences · 2018–2025
    R01GM129380-01
  • MPI
    Intercepting progression from pre-invasive to invasive lung adenocarcinoma
    National Cancer Institute · 2019–2025· 2 renewals
    UG3CA244697-01
  • Co-I
    Studies of the initiation and progression of small cell lung cancer using cells derived by differentiation from human pluripotent stem cells
    National Cancer Institute · 2018–2025
    U01CA224326-05
  • Co-I
    Unraveling the landscape of homologous recombination deficiency in patients with breast and prostate cancer across the African diaspora in NYC
    New York Genome Center Inc. · 2020–2024
    NYG 204878-01
  • Co-I
    Ethnic based differences between Asian and Caucasian patients in genomic, transcriptomic and immune profiles of pre-invasive and invasive adenocarcinoma of the lung
    New York Genome Center Inc. · 2020–2024
    NYGC 211479-01
  • PI
    Astrazeneca UK Limited Biopharma
    ASTRAZENECA UK LIMITED · 2020–2024BioPharma Alliance
    AZ UK 212910-02
  • Co-I
    Core: Targeting Enhancer Dysfunction in Hematological Malignancy- Core B
    Leukemia & Lymphoma Society · 2019–2024 · via University of Florida
    LLS SCOR 7021-20 CORE B
  • Co-I
    Neoantigen Vaccination for Lynch Syndrome Immunoprevention
    National Cancer Institute · 2018–2024
    U01CA233056-01
  • Sub-PI
    High Resolution Molecular Imaging to Elucidate the Contextual Mechanisms of BCG Resistance in Non-muscle Invasive Recurrent Bladder Cancer
    Bladder Cancer Advocacy Network, Inc. · 2022–2024 · via Icahn School of Medicine at Mount Sinai
    No publications yet
    ISMMS 224224-02
  • Co-I
    Defining Molecular Determinants of Lineage Plasticity as a Mechanism of Treatment Resistance in Prostate Cancer
    National Cancer Institute · 2019–2024
    R01CA230913-01A1
  • Co-I
    The Mechanistic Basis Of Radiation Induced Immunomodulation In Early Non-Small Cell Lung Cancer
    U.S. Department of Defense · 2021–2024
    No publications yet
    W81XWH2110309
  • Co-I
    New York City Consortium for Precision Medicine (All of Us Research Program at WCM)
    Office of the Director, NIH · 2018–2024 · via Columbia University
    OT2OD026556-01S3
  • Co-I
    Immune Cells and Secretory Pathways Leading to Human Systemic Autoimmunity
    National Institute of Allergy and Infectious Diseases · 2020–2024
    U19AI144301-03S1
  • MPI
    A novel, short isoform of the +TIP microtubule (MT) binding protein CLIP170 confers taxane resistance by obstructing the MT pore.
    National Cancer Institute · 2018–2024
    R01CA228512-05
  • KP
    Role of Chromatin Remodeling Complex BAF in Immunity and Lymphoma
    National Cancer Institute · 2020–2024· 2 renewals
    K99CA246080-02S1
  • Co-I
    Targeting Genomic, Metabolic and Immunological Vulnerabilities of Colorectal Cancer
    American Association for Cancer Research · 2017–2024 · via Sloan-Kettering Institute for Cancer Research
    SU2C-AACR-DT22-17
  • PI
    Nanostructure-Enhanced Infra-Red Absorption Spectroscopy (NEIRAS) assay to improve Prognosis and Personalized Therapy of Drug-resistant Prostate Cancers
    Cornell University - Ithaca · 2023–2023
    CU 231219-01
  • Co-I
    The Human Distal Airway Aging Project
    National Heart, Lung, and Blood Institute · 2019–2023
    U01HL145561-01
  • MPI
    Longitudinal functional genomics in mantle cell lymphoma therapy and drug resistance
    Leukemia & Lymphoma Society · 2018–2023
    LLS 180078-06
  • Co-I
    A Gata456 Pipeline of Discovery
    National Heart, Lung, and Blood Institute · 2017–2023
    R35HL135778-04
  • MPI
    The Joint WCM-NYGC Center for Functional and Clinical Interpretation of Tumor Profiles
    National Cancer Institute · 2016–2023
    U24CA210989-05
  • Co-I
    Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
    National Cancer Institute · 2017–2023
    P50CA211024-05
  • KP
    Defining the roles of QSER1, a novel regulator of DNA methylation, in stem cell differentiation and development
    Tri-Institutional Stem Cell Initiative (Weill Cornell) · 2021–2023
    Tri-SCI #2021-005
  • Sub-PI
    Inverted Spectroscopic Infrared Microscope (ISIM) for High Throughput Multi-Dimensional Cell Assays
    National Institute of General Medical Sciences · 2021–2023 · via Cornell University - Ithaca
    R21GM138947-02
  • Sub-PI
    Revealing muscle stem cell heterogeneity in mice and humans through deep single-cell analysis
    National Institute on Aging · 2018–2023 · via Cornell University - Ithaca
    R01AG058630-05
  • Sub-PI
    Personalized in vitro models to advance precision medicine
    National Cancer Institute · 2019–2023 · via Leidos Biomedical Research
    HHSN26100008
  • Co-I
    Breaking through immune resistance of HR+ breast cancer
    U.S. Department of Defense · 2019–2023
    No publications yet
    W81XWH1910101
  • Co-I
    The DARC side of Breast Cancer Disparities - African Ancestry and Cancer- Related Immune Response
    National Cancer Institute · 2021–2023
    R01CA259396-01
  • PI
    Spatial Distribution of Sodium Channel Isoforms (Nav1.2 and Nav1.6); a Molecular Mechanism for Neural Circuit Development.
    National Science Foundation · 2019–2022Fellowship
    NSF 191411-01
  • MPI
    Molecular and cellular profiling of preinvasive and minimally invasive lesions to understand the biology underlying progression from indolent to more invasive tumors
    Johnson & Johnson · 2020–2022
    J&J Biopharma 213315-02
  • Co-I
    Clinical and Translational Science Center- Institutional CTSC Internal Funding UL1
    CTSC Cost Share · 2017–2022
    CTSC Internal Funding UL1
  • Co-I
    Biomolecular Markers for Safe Minimization of Immunosuppression
    National Institute of Allergy and Infectious Diseases · 2021–2022
    R37AI051652-15S1
  • PI
    Discovery And Validation Of Novel Therapeutic Strategies In Glioblastoma
    New York Presbyterian Hospital · 2020–2022
    NYPH 205034-01
  • Co-I
    Identification and Targeting of Post-Translationally Modified Neoantigens Presented in BRCA Mutant Tumors
    Gray Foundation · 2019–2022
    GF 193411-01
  • PI
    The Identification and Validation of Mechanisms and Biomarkers for Relapse in Diffuse Large B-Cell Lymphoma
    National Cancer Institute · 2015–2022
    R01CA194547-05
  • Co-I
    CUNY-WCM Big Data Training Program in Biomedical Informatics (BD2BMI)
    National Institute on Minority Health and Health Disparities · 2017–2021 · via Research Foundation of CUNY
    R25MD011713-04
  • KP
    Regulation of ENaC Trafficking and Activity in the Kidney
    National Institute of Diabetes and Digestive and Kidney Diseases · 2017–2021
    R01DK111380-04
  • KP
    Targeting Unmet Clinical Needs for B-Cell Lymphoma
    Leukemia & Lymphoma Society · 2016–2021
    7012-16 CORE A
  • Co-I
    Contribution of H3.3-mediated chromatin dynamics to stem cell pluripotency and developmental potential
    New York State Stem Cell Science (NYSTEM) · 2018–2021
    DOH01-C32581GG-3450000
  • Co-I
    Defining the Cellular Oncogenome of Kaposi Sarcoma
    National Cancer Institute · 2017–2021
    R21CA206851-02
  • MPI
    CENTER ON THE PHYSICS OF CANCER METABOLISM -Microfabrication Core
    National Cancer Institute · 2016–2021 · via Cornell University - Ithaca· 3 renewals
    U54CA210184-04
  • KP
    Precision Medicine Approach to Prostate Cancer Active Surveillance
    National Cancer Institute · 2014–2021
    R01CA184712-05
  • Co-I
    Targeting Cellular Protein Kinases As Treatment For COVID-19
    Pershing Square Foundation · 2020–2021
    PSF 210730-01
  • Co-I
    High dimensional characterization of cancer immune microenvironment by imaging mass cytometry
    Weill Cornell Medical College · 2020–2021
    WCMC 203235-01
  • Co-I
    Biomarkers of Taxane Chemotherapy Response/Resistance in Prostate Cancer
    National Cancer Institute · 2018–2021
    R21CA216800-01A1
  • PI
    DEFINING THE CELLULAR ORIGIN AND MECHANISTIC BASIS FOR THERAPY RESISTANT B-CELL LYMPHOMAS
    Starr Cancer Consortium · 2018–2020
    SCC I11-0027
  • Co-I
    Temporal Evolution of N-Myc Signaling and Early Targeting of the Neuroendocrine Phenotype in Prostate Cancer
    U.S. Department of Defense · 2017–2020
    W81XWH-17-1-0653
  • KP
    SPORE in Bladder Cancer
    National Cancer Institute · 2018–2020 · via Sloan-Kettering Institute for Cancer Research
    P50CA221745-02
  • KP
    Microtubule-Regulated RNA Translation: Implications for Taxane Chemotherapy
    National Cancer Institute · 2014–2020
    R01CA177165-05
  • PI
    Immune Cell Gene Expression and Predictive Models in CFS
    National Institute of Allergy and Infectious Diseases · 2013–2020
    R01AI107762-05
  • Co-I
    Deciphering Molecular Determinants of Vascular Heterogeneity for Organ Repair
    National Heart, Lung, and Blood Institute · 2014–2020
    R01HL128158-05
  • Co-I
    Mechanistic Insights Underlying ERG-Induced Taxane Resistance in Castration-Resistant Prostate Cancer
    National Cancer Institute · 2014–2020
    R01CA179100-05
  • MPI
    Rational Metabolic Engineering as a New Tool for Targeted Intervention in Human Metabolism
    Qatar National Research Fund · 2016–2019
    NPRP 8-061-3-011
  • Sub-PI
    Rational Metabolic Engineering as a New Tool for Targeted Intervention in Human Metabolism
    Qatar National Research Fund · 2016–2019 · via Weill Cornell Medical College/Qatar
    NPRP-8-071-3-011
  • Co-I
    Chromatin Remodeling and FOXO in Targeting CDK4 in Mantle Cell Lymphoma
    American Society of Hematology Inc · 2017–2019
    ASH 170594-01
  • KP
    TET-Dependent Epigenetic Mechanisms Controlling Human Embryonic Stem Cell Differentiation
    Tri-Institutional Stem Cell Initiative (Weill Cornell) · 2016–2019
    2016-032
  • Co-I
    Identification of Antibody Therapeutics for Treatment of Neuroendocrine Prostate Cancer
    Janssen Research & Development, LLC · 2016–2019Contract
    Janssen RAA
  • Co-I
    Using HESC-Derived Lung Cells to Study the Initiation of Small Cell Lung Cancer
    U.S. Department of Defense · 2017–2019
    W81XWH-17-1-0223
  • MPI
    Cohesin Regulatory Proteins and Chromosomal Architecture in Normal and Malignant B-Cells
    National Cancer Institute · 2018–2019
    R01CA228528-01
  • Co-I
    Pathways Controlling mRNA Translation Pathways in Dopaminergic Neurons
    National Institute on Drug Abuse · 2014–2019
    R01DA037755-05
  • Co-I
    Metabolomics Systems Biology Initiatives
    Weill Cornell Medical College/Qatar · 2017–2018Contract
    DUA 181891-01
  • Sub-PI
    Chromatic Mechanisms and Epigenetic Targeting in Hematological Malignancies
    Leukemia & Lymphoma Society · 2012–2018 · via University of Florida
    7006-13
  • Co-I
    Chromatin Remodeling and FOXO in Targeting CDK4 in Mantle Cell Lymphoma
    National Cancer Institute · 2018–2018
    R01CA219957-01A1
  • Co-I
    Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma
    National Cancer Institute · 2014–2018
    R01CA187109-04
  • KP
    Endothelial mTOR Signaling Regulates Hematopoietic Stem Cell Aging
    Tri-Institutional Stem Cell Initiative (Weill Cornell) · 2014–2018
    2014-004
  • PI
    Directing the Timing of Maturation in Human Pluripotent Stem Cell-Derived Neurons
    Tri-Institutional Stem Cell Initiative (Weill Cornell) · 2016–2018
    TSCI 2016-025
  • Co-I
    CDCP1
    Pfizer Centers for Therapeutic Innovation · 2014–2018 · via Beth Israel Deaconess Medical Center, Inc.
    No publications yet
    BIDMC 170116-01
  • Co-I
    Columbia/Cornell/Harlem Hospital Precision Medicine Initiative HPO
    Office of the Director, NIH · 2016–2018 · via Columbia University· 2 renewals
    UG3OD023183-01
  • Sub-PI
    Mechanisms of Sphingolipid Signaling in Vascular Health and Disease
    National Heart, Lung, and Blood Institute · 2017–2018 · via Boston Children's Hospital (Children's Hospital Corporation)
    R35HL135821-01
  • PI
    A rational immuno-oncology strategy to target tumor associated stromal cells using untibodies.
    Sanofi S.A. · 2016–2017Contract
    Sanofi RAA
  • KP
    Targeting the Heat Shock Response for the Therapy of DLBCL
    National Cancer Institute · 2011–2016
    R01CA155226-05
  • KP
    Transcriptional Silencing by the BCL6 Oncoprotein
    National Cancer Institute · 2010–2015
    R01CA104348-10
  • KP
    Exome Re-Sequencing Candidate Loci for Familial Essential Tremor
    National Institute of Neurological Disorders and Stroke · 2011–2013
    R21NS075397-01
  • KP
    Software Systems for Detecting Rare Mutations
    National Human Genome Research Institute · 2011–2012 · via Geospiza, Inc.
    R44HG005297-03

Clinical research

3 studies

Active

1 study
  • PI
    Immunophenotypic and Genomic Characterization of Mantle Cell Lymphoma
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2020)
Completed & closed trials (2)
  • PI
    COVID-19 racial Disparities, DARC side of SARS-CoV-2
    Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2025)
  • PI
    NYGC COVID Genomics Research Network
    New York Genome Center Inc. · IRB STUDY CLOSURE (as of 2023)

Available technologies

1 technologyView full WCM portfolio ↗

News mentions

37 mentionsView all WCM news ↗
Show 32 more mentions

Media highlights

5 clips

Mentoring

27 menteesAll publications with mentees →
3 MD students · 20 PhD students · 4 Postdocs

External relationships

Ownership

Exai Bio INC · Freenome · Owkin France · Volastra

Advisory/Scientific Board Member

Exai Bio INC · New York Stem Cell Foundation Inc. · Owkin France · Pershing Square Sohn Cancer Research Alliance, The · Volastra

Proprietary Interest

Center for Technology Licensing at Cornell University

Other Interest

Volastra